Skip to main content

SARS-CoV-2 nsp8 Antibody [Janelia Fluor® 525]

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-07047JF525

Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Validated:

SARS-CoV-2

Predicted:

SARS-CoV (100%). Backed by our 100% Guarantee.

Applications

ELISA, Western Blot

Label

Janelia Fluor 525

Antibody Source

Polyclonal Rabbit IgG

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Product Specifications

Immunogen

This antibody was raised against a peptide corresponding to 14 amino acids near the center of SARS-CoV-2 (COVID-19) NSP8 protein. The immunogen is located within 40-90 amino acids of SARS-CoV-2 (COVID-19) NSP8.

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Applications for SARS-CoV-2 nsp8 Antibody [Janelia Fluor® 525]

Application
Recommended Usage

ELISA

Optimal dilutions of this antibody should be experimentally determined.

Western Blot

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Peptide affinity purified

Formulation

50mM Sodium Borate

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: SARS-CoV-2 nsp8

SARS-CoV-2 Nonstructural Protein 8 (NSP8) is one of the sixteen nonstructural proteins of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19 (1). SARS-CoV-2 NSP8 is 198 amino acids (aa) with a theoretical molecular weight of 21.9 kDa (1,2). The amino acid sequence alignment of SARS-CoV and SARS-CoV-2's NSP8 has 97.5% sequence identity and 100% sequence similarity (1). SARS-CoV-2 NSP8 heterodimerizes with NSP7, which forms a complex with NSP12 (1-4). NSP8 alone in its monomeric form can also complex with NSP12, generating the RNA polymerase complex (1,4). Additionally, NSP8 is shown to interact with the SARS-CoV-2 open reading frame 6 (ORF6), encouraging RNA polymerase activity (1).

References

1. Yoshimoto F. K. (2020). The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19. The Protein Journal. https://doi.org/10.1007/s10930-020-09901-4

2. Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O'Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., Tummino, T. A., Huttenhain, R., Kaake, R. M., Richards, A. L., Tutuncuoglu, B., Foussard, H., Batra, J., Haas, K., Modak, M., Kim, M., ... Krogan, N. J. (2020). A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. https://doi.org/10.1038/s41586-020-2286-9

3. Qiu, Y., & Xu, K. (2020). Functional studies of the coronavirus nonstructural proteins. STEMedicine. https://doi.org/10.37175/stemedicine.v1i2.39

4. Peng, Q., Peng, R., Yuan, B., Zhao, J., Wang, M., Wang, X., Wang, Q., Sun, Y., Fan, Z., Qi, J., Gao, G. F., & Shi, Y. (2020). Structural and Biochemical Characterization of the nsp12-nsp7-nsp8 Core Polymerase Complex from SARS-CoV-2. Cell reports. https://doi.org/10.1016/j.celrep.2020.107774

Alternate Names

Non-structural protein 8, nsp8 replicase

Gene Symbol

ORF1ab

Additional SARS-CoV-2 nsp8 Products

Product Documents for SARS-CoV-2 nsp8 Antibody [Janelia Fluor® 525]

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for SARS-CoV-2 nsp8 Antibody [Janelia Fluor® 525]



Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...